Short answer
Denali Therapeutics Inc. (DNLI) filed an 8-K current report with the SEC on April 3, 2026 reporting Item 1.02 (Termination of a Material Definitive Agreement), Item EX-99.1 (Exhibit EX-99.1). Takeda terminating DNL593 collaboration, effective June 2, 2026.
Denali Therapeutics Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.02 · Termination of a Material Definitive Agreement
- Takeda terminating DNL593 collaboration, effective June 2, 2026
- Termination attributed to strategic considerations, not efficacy or safety concerns
- DNL593 rights reverting fully to Denali after termination
- Denali eliminating future financial obligations to Takeda for the program
Item EX-99.1 · Exhibit EX-99.1
- Takeda terminated the DNL593 collaboration for strategic reasons, not efficacy or safety, returning full rights and intellectual property to Denali
- Denali assumes sole responsibility for DNL593 development, increasing control but also future funding and execution requirements
- Phase 1/2 enrollment completed with 40 FTD-GRN participants; results and biomarker data expected by end of 2026
- Interim healthy-volunteer data showed dose-dependent cerebrospinal-fluid progranulin increases and no significant safety signals to date
- DNL593 targets FTD-GRN, an area with no approved treatments to slow disease progression
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Denali Therapeutics Inc. 8-K filings
Get the next DNLI 8-K as it lands
Follow DNLI for push alerts, or ask the research agent what this filing means.